Valneva reports 'positive' COVID vaccine results

COVID vaccine
Credit: Pixabay/CC0 Public Domain

Franco-Austrian biotech lab Valneva announced Monday positive results from clinical trials of its COVID vaccine candidate, a month after the UK government terminated a supply deal with the company.

Britain had ordered 100 million doses of the vaccine for 2021-2022—the only order so far for Valneva, which has a in Scotland.

The French government has said that the European Union was still in negotiations to buy the vaccine.

Valvena said its Phase 3 trial, conducted among 4,012 adults in Britain, showed "positive" results for the vaccine, providing more neutralising antibodies than the shot made by British pharmaceutical giant AstraZeneca.

Valneva's VLA2001 vaccine is based on an "inactivated" version of the coronavirus itself to ward off COVID-19.

"This is a much more traditional approach to vaccine manufacture than the vaccines so far deployed in the UK, Europe and North America," said Adam Finn, professor of paediatrics at University of Bristol and the chief investigator.

"These results suggest this is on track to play an important role in overcoming the pandemic," Finn said in a company statement.

Valneva's shares soared by more than 30 percent following the announcement. They had sunk after Britain cancelled its contract last month.

The company said it has begun the vaccine approval process with the UK's health regulator and is preparing to submit a request with the European Medicines Agency.

"We are committed to bringing our differentiated vaccine candidate to licensure as quickly as possible and continue to believe that we will be able to make an important contribution to the global fight against the COVID-19 pandemic," said Valneva CEO Thomas Lingelbach.

Explore further

UK cancels COVID vaccine contract with Franco-Austrian firm

© 2021 AFP

Citation: Valneva reports 'positive' COVID vaccine results (2021, October 18) retrieved 3 December 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors